SONALASENSE, INC.

Address: 904 ALVARADO RD BERKELEY, CA 94705-4036
County: ALAMEDA
Country: UNITED STATES
UEI: LC3GHFGF2KK1

Issue Date FY

Legal Entity Zip Code

Issue Date FY: 2025 ( Subtotal = $9,854,457 )

2025

SONALASENSE, INC.

1111 BROADWAY

OAKLAND

94607-4036

ALAMEDA

USA

AY2AX000034

The Development of a Novel Molecular Platform, Non-Invasive Sonodynamic Therapeutic Devices, for the treatment of Hematologic Malignancies

000

NIH

12/11/2024

$9,115,161

2025

SONALASENSE, INC.

904 ALVARADO RD

BERKELEY

94705-1550

ALAMEDA

USA

AY2AX000034

The Development of a Novel Molecular Platform, Non-Invasive Sonodynamic Therapeutic Devices, for the treatment of Hematologic Malignancies

001

NIH

4/17/2025

2025

SONALASENSE, INC.

904 ALVARADO RD

BERKELEY

94705-1550

ALAMEDA

USA

AY2AX000034

The Development of a Novel Molecular Platform, Non-Invasive Sonodynamic Therapeutic Devices, for the treatment of Hematologic Malignancies

002

NIH

6/24/2025

2025

SONALASENSE, INC.

904 ALVARADO RD

BERKELEY

94705-1550

ALAMEDA

USA

AY2AX000034

The Development of a Novel Molecular Platform, Non-Invasive Sonodynamic Therapeutic Devices, for the treatment of Hematologic Malignancies

003

NIH

8/29/2025

2025

SONALASENSE, INC.

904 ALVARADO RD

BERKELEY

94705-1550

ALAMEDA

USA

R44CA275508

Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme

000

NIH

9/5/2025

$796,215

2025

2024

SONALASENSE, INC.

904 ALVARADO RD

BERKELEY

94705-1550

ALAMEDA

USA

R01FD007538

Drug and energy dose-escalation study of SONALA-001 sonodynamic therapy in the treatment of diffuse intrinsic pontine glioma

000

FDA

4/9/2025

2025

2023

SONALASENSE, INC.

904 ALVARADO RD

BERKELEY

94705-1550

ALAMEDA

USA

R44CA261516

Evaluation of the safety and efficacy of non-invasive sonodynamic therapy for diffuse intrinsic pontine glioma

000

NIH

1/31/2025

-$56,919

Issue Date FY: 2024 ( Subtotal = $0 )

2024

SONALASENSE, INC.

1111 BROADWAY

OAKLAND

94607-4036

ALAMEDA

USA

R01FD007538

Drug and energy dose-escalation study of SONALA-001 sonodynamic therapy in the treatment of diffuse intrinsic pontine glioma

000

FDA

7/23/2024

$488,085

2024

SONALASENSE, INC.

1111 BROADWAY

OAKLAND

94607-4036

ALAMEDA

USA

R01FD007538

Drug and energy dose-escalation study of SONALA-001 sonodynamic therapy in the treatment of diffuse intrinsic pontine glioma

002

FDA

8/21/2024

-$488,084

2024

SONALASENSE, INC.

1111 BROADWAY

OAKLAND

94607-4036

ALAMEDA

USA

R01FD007538

Drug and energy dose-escalation study of SONALA-001 sonodynamic therapy in the treatment of diffuse intrinsic pontine glioma

003

FDA

9/4/2024

2024

SONALASENSE, INC.

1111 BROADWAY

OAKLAND

94607-4036

ALAMEDA

USA

R01FD007538

Drug and energy dose-escalation study of SONALA-001 sonodynamic therapy in the treatment of diffuse intrinsic pontine glioma

001

FDA

7/24/2024

-$1

2024

2023

SONALASENSE, INC.

1111 BROADWAY

OAKLAND

94607-4036

ALAMEDA

USA

R44CA275508

Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme

000

NIH

6/21/2024

2024

2023

SONALASENSE, INC.

1111 BROADWAY

OAKLAND

94607-4036

ALAMEDA

USA

R44CA261516

Evaluation of the safety and efficacy of non-invasive sonodynamic therapy for diffuse intrinsic pontine glioma

000

NIH

8/12/2024

2024

2023

SONALASENSE, INC.

1111 BROADWAY

OAKLAND

94607-4036

ALAMEDA

USA

R44CA275508

Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme

002

NIH

9/26/2024

2024

2023

SONALASENSE, INC.

1111 BROADWAY

OAKLAND

94607-4036

ALAMEDA

USA

R44CA275508

Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme

001

NIH

8/8/2024

Issue Date FY: 2023 ( Subtotal = $1,755,859 )

2023

SONALASENSE, INC.

1111 BROADWAY

OAKLAND

94607-4036

ALAMEDA

USA

R44CA261516

Evaluation of the safety and efficacy of non-invasive sonodynamic therapy for diffuse intrinsic pontine glioma

000

NIH

4/12/2023

$1,061,045

2023

SONALASENSE INC

1111 BROADWAY

OAKLAND

94607-4036

ALAMEDA

USA

R44CA275508

Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme

000

NIH

3/21/2023

$694,814

2023

2022

SONALASENSE, INC.

1111 BROADWAY

OAKLAND

94607-4036

ALAMEDA

USA

R01FD007538

Drug and energy dose-escalation study of SONALA-001 sonodynamic therapy in the treatment of diffuse intrinsic pontine glioma

000

FDA

7/19/2023

Issue Date FY: 2022 ( Subtotal = $1,415,961 )

2022

SONALASENSE INC

2600 10TH ST STE 435

BERKELEY

94710-3105

ALAMEDA

USA

R44CA261516

Evaluation of the safety and efficacy of non-invasive sonodynamic therapy for diffuse intrinsic pontine glioma

000

NIH

4/15/2022

$938,955

2022

SONALASENSE INC

2600 10TH ST STE 435

BERKELEY

94710-3105

ALAMEDA

USA

R01FD007538

Drug and energy dose-escalation study of SONALA-001 sonodynamic therapy in the treatment of diffuse intrinsic pontine glioma

000

FDA

9/22/2022

$477,006

All Categories

About

Search

Reports

Data Submission

Recipient Information

SONALASENSE, INC.

Address: 904 ALVARADO RD BERKELEY, CA 94705-4036

County: ALAMEDA

Country: UNITED STATES

UEI: LC3GHFGF2KK1

Issue Date FY Summary

Issue Date FY by OPDIV

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer